Piramal Pharma Ltd. shares rise by more than 10% following news that the company has received over 70 regulatory approvals globally during the past fiscal year. The reported approvals are cited as the main factor behind the rally, suggesting continued progress in securing authorizations across multiple markets. No additional operational or financial details are mentioned in the provided accounts, including whether the approvals relate to specific products, new launches, or renewals. The coverage focuses on the scale of regulatory clearance and its potential to support the company’s pipeline and market access. Overall, the articles present the surge as being driven by the regulatory milestone, with the positive market reaction reflected in the sharp increase in the share price. The reports do not specify the company’s guidance, earnings updates, or broader market context within the excerpts provided.